Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy

NCT04787276 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Hepatic Encephalopathy
Liver Cirrhosis
End Stage Liver DIsease

Interventions

DIETARY_SUPPLEMENT: E.coli Nissle 1917
DRUG: Lactulose
DRUG: Rifaximin

Sponsor

Bogomolets National Medical University